3 Reasons Cara Therapeutics Is a Better Growth Stock Than Novavax
At one point this year, Cara Therapeutics (NASDAQ: CARA) stock was up more than 175%. Most of those gains were given up, though. The stock is now up a little over 30% year to date. But that's still a better performance than Novavax (NASDAQ: NVAX) has achieved. At its peak this year, Novavax stock was up close to 30%. It's now down more than 10% year to date.
Short-term stock performance doesn't necessarily make one stock better than another. However, I think Cara Therapeutics has better growth potential than Novavax does over the near term and probably over the long run, as well. Here are three reasons why.
Image source: Getty Images.
Source: Fool.com
Novavax Inc. Stock
€14.52
5.620%
Our community is currently high on Novavax Inc. with 5 Buy predictions and 3 Sell predictions.
On the other hand, the target price of 9 € is below the current price of 14.52 € for Novavax Inc., so the potential is actually -38.03%.
